Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct:133:107374.
doi: 10.1016/j.leukres.2023.107374. Epub 2023 Aug 22.

Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy

Fatima M Khadadah  1 , Sonia Cerquozzi  2 , Harold J Olney  3 , Christina Fraga  4 , Jill Dudebout  5 , Anargyros Xenocostas  6 , Nicholas Finn  7 , Vincent Ethier  8 , M Lynn Savoie  2 , Lambert Busque  9 , Kareem Jamani  2 , Philip Kuruvilla  10 , Carolyn Faught  11 , Brian Leber  12 , Rayan Kaedbey  13 , Sarit E Assouline  14 , Dennis Kim  15
Affiliations

Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy

Fatima M Khadadah et al. Leuk Res. 2023 Oct.

Abstract

Background: Asciminib is a novel drug specifically targeting ABL myristoyl pocket in the ABL1 protein.

Methods: Forty one patients with chronic myeloid leukemia treated with asciminib from 2018 to 2022 were reviewed and analyzed for the efficacy and tolerability of asciminib using real-world experience data.

Results: The median age was 60 years (range 17-90) with a past history of a cardiovascular event in 21 patients (51%). Patients were pretreated with a median of 3 previous tyrosine kinase inhibitors (range 1-5). After a median of 12 months of asciminib (range 3-41), major molecular response (MMR) rate was 39% (n = 11/28) and 42% (n = 5/12) at 6 and 12 months, respectively. Molecular response with 2 log reduction (MR2) was noted in 54% (n = 15/28) and 50% (n = 6/12) at 6 and 12 months. The cumulative incidence of MMR and MR2 was 46.3% and 66% at 12 months. Five patients discontinued asciminib due to treatment failure (n = 3) or thrombocytopenia (n = 2). There were no cardiovascular events. Out of 7 patients treated with high dose asciminib for T315I mutation, 5 patients achieved MMR or deeper response. The event-free survival was 63% at 12 months.

Conclusion: This study confirmed clinical efficacy and tolerability of asciminib with real-world experience.

Keywords: Asciminib; Chronic myeloid leukemia; Real-world evidence; Tyrosine kinase inhibitors.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest FK provides consultancy for Novartis, SC provides consultancy and has honoraria for Novartis, Pfizer, BMS, Celgene, Incite. AX, NF and LB has honoraria from Novartis. BL provides consultancy, has honoraria and on the advisory board for Novartis, Pfizer, BMS, Abbvie, and AMGEN. RK is on the advisory boards of Sanofi, FORUS Therapeutics, Belgene, Pfizer and has honoraria from Janssen and BMS. SA gets research funding from Novartis and has consultancy/ honoraria from Genentech/Roche, Astra Zeneca, Novartis, BMS, Jazz, Gilead, Amgen, Beigene, Abbvie, Paladin. DK is a consultant, has received research funding, and honoraria from Pfizer, Sanofi, Paladin, and Novartis. The remaining authors have no conflict of interest.

Publication types

LinkOut - more resources